4:03 PM
 | 
Jun 12, 2018
 |  BC Extra  |  Company News

FDA approves Keytruda in cervical cancer

Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy in patients whose tumors express PD-L1, with a Combined Positive Score (CPS) of ≥1 as determined by an FDA-approved test. The pharma said Keytruda is the first PD-1 inhibitor approved to treat advanced cervical cancer.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD